Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-126370
Filing Date
2024-11-13
Accepted
2024-11-13 16:27:31
Documents
93
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q fdmt-20240930.htm   iXBRL 10-Q 2883958
2 EX-4.4 fdmt-ex4_4.htm EX-4.4 151078
3 EX-31.1 fdmt-ex31_1.htm EX-31.1 19832
4 EX-31.2 fdmt-ex31_2.htm EX-31.2 19758
5 EX-32.1 fdmt-ex32_1.htm EX-32.1 12258
  Complete submission text file 0000950170-24-126370.txt   11154812

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT fdmt-20240930.xsd EX-101.SCH 1521381
96 EXTRACTED XBRL INSTANCE DOCUMENT fdmt-20240930_htm.xml XML 1885638
Mailing Address 5858 HORTON STREET #455 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET #455 EMERYVILLE CA 94608 5105052680
4D Molecular Therapeutics, Inc. (Filer) CIK: 0001650648 (see all company filings)

EIN.: 473506994 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39782 | Film No.: 241454763
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)